Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
Identifieur interne : 000D77 ( Ncbi/Curation ); précédent : 000D76; suivant : 000D78Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
Auteurs : Dirk Dressler [Allemagne]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Action Potentials (drug effects), Animals, Anti-Dyskinesia Agents (immunology), Anti-Dyskinesia Agents (therapeutic use), Antibodies (immunology), Antibody Formation (drug effects), Antibody Formation (physiology), Botulinum Toxins (immunology), Botulinum Toxins (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Electromyography, Enzyme-Linked Immunosorbent Assay (methods), Humans, Muscles (drug effects), Reaction Time, Time Factors, Torticollis (drug therapy), Torticollis (physiopathology), Treatment Failure.
- MESH :
- chemical , immunology : Anti-Dyskinesia Agents, Antibodies, Botulinum Toxins.
- drug effects : Action Potentials, Antibody Formation, Muscles.
- drug therapy : Torticollis.
- methods : Enzyme-Linked Immunosorbent Assay.
- physiology : Antibody Formation.
- physiopathology : Torticollis.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- Animals, Dose-Response Relationship, Drug, Drug Administration Schedule, Electromyography, Humans, Reaction Time, Time Factors, Treatment Failure.
Abstract
Therapy with botulinum toxin (BT) can fail due to numerous reasons, including failure due to formation of antibodies against BT (BT-AB, AB-TF). AB-TF is a secondary therapy failure, i.e. it occurs during the course of an ongoing BT therapy. It can be subjective or objective, temporary or permanent, and partial or complete. Complete AB-TF is usually preceded by injection series with partial AB-TF in which the therapeutic effect is reduced in its intensity and duration. AB-TF usually occurs within 2 or 3 years after initiation of BT therapy. After 4 years it is rare. BT-AB are neutralising or blocking by definition, i.e. they are directly interfering with BT's biological mechanism of action. Non-neutralizing or non-blocking antibodies occur. BT-AB can be detected by the mouse diaphragm assay, the mouse protection assay, and by patient-based tests such as the sternocleidomastoid test, the extensor digitorum brevis test, and the frowning test. Enzyme-linked immunosorbent assays (ELISA) have a low specificity and a low sensitivity for detection of BT-AB. BT-AB titres drop spontaneously after cessation of BT therapy but latencies are too long to be compatible with an effective BT therapy. BT dosage increase can be successful to overcome AB-TF when AB-TF is partial and when BT-AB titres are low. Usage of alternative BT type A preparations fail to overcome AB-TF. Alternative BT types, such as BT type B and BT type F, are initially successful in AB-TF, but stimulate formation of antibodies against the alternative BT types after few applications. BT-AB reduction with immunosuppressants and inactivation of BT-AB by intravenous immunoglobuline application has not yet been achieved. Extraction of BT-AB by plasmapheresis and immunoadsorption is possible but is associated with substantial logistic problems. Prevention of BT-AB formation, therefore, is of paramount importance. Identified risk factors for BT-AB formation must be taken into account when BT therapy is planned. The most interesting perspective seems to be the development of new BT preparations with reduced antigenicity.
DOI: 10.1002/mds.20022
PubMed: 15027060
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003507
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003507
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003517
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000D77
Links to Exploration step
pubmed:15027060Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Rostock University, Rostock, Germany. dirk.dressler@med.uni-rostock.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15027060</idno>
<idno type="pmid">15027060</idno>
<idno type="doi">10.1002/mds.20022</idno>
<idno type="wicri:Area/PubMed/Corpus">003507</idno>
<idno type="wicri:Area/PubMed/Curation">003507</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003517</idno>
<idno type="wicri:Area/Ncbi/Merge">000D77</idno>
<idno type="wicri:Area/Ncbi/Curation">000D77</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Rostock University, Rostock, Germany. dirk.dressler@med.uni-rostock.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (drug effects)</term>
<term>Animals</term>
<term>Anti-Dyskinesia Agents (immunology)</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Antibodies (immunology)</term>
<term>Antibody Formation (drug effects)</term>
<term>Antibody Formation (physiology)</term>
<term>Botulinum Toxins (immunology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Electromyography</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Humans</term>
<term>Muscles (drug effects)</term>
<term>Reaction Time</term>
<term>Time Factors</term>
<term>Torticollis (drug therapy)</term>
<term>Torticollis (physiopathology)</term>
<term>Treatment Failure</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Antibodies</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Action Potentials</term>
<term>Antibody Formation</term>
<term>Muscles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Antibody Formation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Electromyography</term>
<term>Humans</term>
<term>Reaction Time</term>
<term>Time Factors</term>
<term>Treatment Failure</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Therapy with botulinum toxin (BT) can fail due to numerous reasons, including failure due to formation of antibodies against BT (BT-AB, AB-TF). AB-TF is a secondary therapy failure, i.e. it occurs during the course of an ongoing BT therapy. It can be subjective or objective, temporary or permanent, and partial or complete. Complete AB-TF is usually preceded by injection series with partial AB-TF in which the therapeutic effect is reduced in its intensity and duration. AB-TF usually occurs within 2 or 3 years after initiation of BT therapy. After 4 years it is rare. BT-AB are neutralising or blocking by definition, i.e. they are directly interfering with BT's biological mechanism of action. Non-neutralizing or non-blocking antibodies occur. BT-AB can be detected by the mouse diaphragm assay, the mouse protection assay, and by patient-based tests such as the sternocleidomastoid test, the extensor digitorum brevis test, and the frowning test. Enzyme-linked immunosorbent assays (ELISA) have a low specificity and a low sensitivity for detection of BT-AB. BT-AB titres drop spontaneously after cessation of BT therapy but latencies are too long to be compatible with an effective BT therapy. BT dosage increase can be successful to overcome AB-TF when AB-TF is partial and when BT-AB titres are low. Usage of alternative BT type A preparations fail to overcome AB-TF. Alternative BT types, such as BT type B and BT type F, are initially successful in AB-TF, but stimulate formation of antibodies against the alternative BT types after few applications. BT-AB reduction with immunosuppressants and inactivation of BT-AB by intravenous immunoglobuline application has not yet been achieved. Extraction of BT-AB by plasmapheresis and immunoadsorption is possible but is associated with substantial logistic problems. Prevention of BT-AB formation, therefore, is of paramount importance. Identified risk factors for BT-AB formation must be taken into account when BT therapy is planned. The most interesting perspective seems to be the development of new BT preparations with reduced antigenicity.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000D77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:15027060 |texte= Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15027060" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |